VolitionRx Announces Board Streamlining as Director Departs

VolitionRX ( (VNRX) ) has provided an announcement.

On May 12, 2026, VolitionRx Limited disclosed that board member Mickie Henshall, who has served since August 2022, will not stand for re-election at the company’s 2026 Annual Meeting of Stockholders, with the company noting that her decision did not stem from any disagreement over its operations, policies or practices. In conjunction with her planned departure, the board will be reduced from eight to seven directors immediately prior to the 2026 Annual Meeting, signaling a modest streamlining of the company’s governance structure without indicating broader strategic shifts.

The governance adjustment is expected to proceed smoothly given the absence of reported disputes, and it maintains continuity for shareholders as the company heads into its 2026 meeting cycle.

The most recent analyst rating on (VNRX) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.

Spark’s Take on VNRX Stock

According to Spark, TipRanks’ AI Analyst, VNRX is a Neutral.

The score is primarily held back by weak financial performance (large losses, negative equity, and significant cash burn), reinforced by bearish technicals. The earnings call provides some offset through commercialization/scientific milestones and cost-cutting/liquidity actions, but valuation support is limited given ongoing losses and no dividend.

To see Spark’s full report on VNRX stock, click here.

More about VolitionRX

VolitionRx Limited operates in the life sciences sector, developing diagnostic technologies and related services. The company focuses on advancing tools and solutions that support clinical and healthcare decision-making for stakeholders across its markets.

Average Trading Volume: 605,491

Technical Sentiment Signal: Sell

Current Market Cap: $17.79M

For detailed information about VNRX stock, go to TipRanks’ Stock Analysis page.